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iw-X : O: ed with TS were protected from the cyto-
:TS(10 irt _ toxic effects of zidovudine (AZT). Fur-
thermore, Chinese hamster V-79 cells pre-
(2~9 orally) reviciry~ treated with TS were protected from chro
suget. ot ts t mate- (11) and ultraviolet-B light- (12) -....... -....
induced cytotoxicity. These findings sug-
--X- gest TS-mediated cytoprotection is not
selective for a particular chemical or toxic
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insult, cell type, or species. In fact, the
::: : :: R::::diversity of these insults suggests that the X observed cytoprotection may result from the
ability ofTS to intervene in the critical cel-
X lular events that lead to toxic cell death.
The investigators of the studies men-
of tioned above suggest that TS cytoprotection
(elev ALT. results from the enhanced cellular release
and accumulation of unesterified x-toco-
Xes.SSM pherol (T, a membrane-bound antioxidant
and free radical scavenger (2-4, 7-12).
df... However, our studies using rat hepatocyte
suspensions do not support this conclusion.
Instead, we have demonstrated that incuba-
*;'-_..l.. "*S. ...S h" " "' "' s~~~ ::tion of hepatocytes with T or tocopheryl
of..........Tacetate (TA) results in elevated cellular cc-
tocopherol and TA levels, respectively, but
does not protect cells from toxic injury
I..mle.e......... (1,5,6). From these studies, we have con-
cluded that TS cytoprotection is unique and
- depends on the cellular accumulation ofthe
TS molecule and not T
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ne possible lack
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Attempting to exclude this possibility, we
investigated the protective effect of in vivo
TS administration (and other tocopherol
analogs) on carbon tetrachloride-induced
toxicity in rats. Furthermore, to assess the
importance of the tocopherol molecule in
cytoprotection, we also investigated the pro-
tective properties ofanother lipophilic suc-
cinate derivative, cholesteryl hemisuccinate
(CS).
Materials and Methods
Di[tris(hydroxymethyl)-aminomethane]
succinate (trizma succinate), tris(hydrox-
ymethyl)aminomethane (trizma base), sodi-
um succinate, cholesteryl acetate (CA;
99%), cholesteryl hemisuccinate, tris salt
(99%, CS), dl-a-tocopheryl nicotinate
(TN; 99%), 2-methyl-1,2-di-3-pyridyl-1-
propanone (metyrapone; 98+%) were pur-
chased from Sigma Chemical Co., St.
Louis, Missouri. Carbon tetrachloride
(CC14; 99+%) and cholesterol (98%) were
purchased from Aldrich Chemical Co.,
Milwaukee, Wisconsin; d-a-tocopherol (T;
98%), d-a-tocopheryl hemisuccinate, free
acid (TS; 99%), and d-a-tocopheryl acetate
(TA; 99%) were gifts from The Henkel
Corp., LaGrange, Illinois.
The method ofJanoff et al. (13) was
modified to prepare the tris salt of TS.
Trizma base (7.5 mM or 913 mg) was dis-
solved in 25 ml ofhot methanol. In a sepa-
rate flask, TS (7.5 mM or 4.0 g) was dis-
solved in 25 ml ofdiethyl ether. Each solu-
tion was cooled to room temperature,
mixed, and placed on a rotoevaporator
under negative pressure. Once solvents
were removed, we washed the resulting
gelatinous white solid in diethyl ether (4
ml), stirred it, and allowed it to sit over-
night. The etherwas removedwith a rotoe-
vaporator and the resulting white solid
dried in a desiccator containing calcium
chloride. The melting point of the final
product (4.5 g, 91% yield) was 88-910C,
and the purity was greater than 98+% as
determined by acid/base titration of the
amount of trizma base and TS, free acid
present in the final product.
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For the experiments described in
Tables 1-3, dosing solutions ofT, TA, and
TS free acid were prepared by dissolving
the compounds in ethanol (2 parts) fol-
lowed by peanut oil (3 parts) at a concen-
tration of 100 mg/ml. In the experiments
described in Tables 4 and 5, dosing solu-
tions of cholesterol, CA, TS, and CS, tris
salt were prepared at 25 mg/ml by dissolv-
ing the compounds in ethanol (1 part) fol-
lowed by 3 parts olive oil (for cholesterol
and CA) or polyethylene glycol 400 (for
TS and CS). In the experiments described
in Tables 6 and 7, dosing solutions (25
mg/kg) ofTN, TS free acid and cholesterol
were dissolved in olive oil (25 mg/ml),
whereas the tris salts of TS and CS were
fine suspensions (sonicated) of 25 mg/ml
saline. The dosing solution of CC14 was
dissolved in peanut oil (1 g/ml), and
metyrapone was dissolved in corn oil (50
mg/ml). We prepared all dosing solutions
immediately before administration.
Male Sprague-Dawley rats (175-275
g), given food and water ad libitum, were
used for these experiments. Experimental
animals were given an intraperitoneal (ip)
injection or oral gavage oftocopherol ana-
log (100 mg/kg body weight), cholesterol
analog (100 mg/kg), or vehicle and fasted
(as noted, several experiments used only
fed rats). Twenty four hours later, each
animal received CC14 (1.0 to 2.9 g/kg
bodyweight) orpeanut oil (vehicle) byoral
gavage. One hour after CC14 administra-
tion, each animal received food and water
adlibitum. We assessed hepatotoxicity 24,
48, or 72 hr after CC14 administration and
monitored survival for 7 days in the acute
toxicity experiments (Table 1).
Hepatotoxicity was determined by
measuring serum AST and ALT levels and
liver histopathology. Using ether anesthe-
sia, we collected serum from the inferior
aorta (at sacrifice) or from the tail vein at
24 or 48 hrafter CC14 administration. We
determined serum AST and ALT levels
with a Roche Cobas Bio Clinical Analyzer
using the spectrophotometric method
adopted from Bergmeyer et al. (14).
For histopathology, we sacrificed ex-
perimental animals 48 or 72 hr after CC14
administration with ether anesthesia and
exsanguination. The liver (or other tissues)
was immediately removed, weighed, sliced
into 2- to 3-mm sections, and fixed in
10% neutral buffered formalin. After 48
hr of fixation, tissues were paraffin infil-
trated on a Miles Tissue-Tek VIP tissue
processor. Four micron histologic sections
were cut on a Reichert Histostat Rotary
microtome and mounted on glass slides.
All sections were stained with Harris hema-
toxylin and eosin (H&E) on a Shandon
Varistain 24-3. In several experiments
(described in Figure 2), liver tissue was cut
Table 1. Effectoftocopherol analog administration onthe acutetoxicity ofCCI4
Survival after CCI4treatment
(g CCI kg) Estimated
Tocopherol analog administereda 5.0 3.8 2.9 2.2 1.7 1.3 LD5
Vehicle ND - - + ND ND 2.5
Tocopherol
(100 mg/kg, ip) ND ND - - - + 1.5
Tocopheryl acetate
(100 mg/kg, ip) ND - - + ND ND 2.5
Tocopheryl succinate
(100 mg/kg, ip) - + + ND ND ND 4.4
Tocopheryl succinate
(100mg/kg,oral) ND - - + ND ND 2.5
8Tocopherol analogs and vehicle were administered and rats fasted for 24 hr before CCI4treatment.
Survival is noted as + and results representthree to nine ratstested pertreatment. LD5 valueswere esti-
mated bythe up-and-down method of Dixon (15) and Bruce(16). ND, notdetermined.
into 1-mm cubes and fixed in 2% phos-
phate-buffered glutaraldehyde for 3 hr.
After a phosphate buffer rinse, the tissues
were postfixed 1 hr in 1% osmium tetrox-
ide, dehydrated with ethanol, and embed-
ded in Poly/Bed epoxy resin (Polysciences
Inc., Warrington, Pennsylvania). Sections
were cut 1 ,um thick and stained with 1%
toluidine blue. Histologic sections were
examined (as described below) by a pathol-
ogist without knowledge of experimental
treatment. To quantify CC14-induced
hepatocellular necrosis, each histologic
liver section was rated for necrosis on a
scale of 0-4 or was examined for the per-
centage ofliver necrosis as measured with a
ZeissVideoplan system.
We examined multiple liver histologic
cross-sections from each experimental ani-
mal and scored them as to the extent of
liver necrosis using a scale of0-4. The cri-
teria for each score are as follows: 0 = no
necrosis; 1 = necrosis limited to proximal
perivenular (centrilobular) layers ofhepa-
tocytes without extending into the mid-
zonal (mid-third between portal triad and
terminal venule/central vein) region; 2 =
necrosis ofentire perivenular zone extend-
ing into the midzonal region, up to one-
half the span of the hepatic lobule; 3 =
necrosis of more than one-half of the
hepatic lobule extending to within a few
cell layers ofthe portal triad; and 4 = com-
plete necrosis
To determine the percentage of liver
necrosis (% ofliver), a histologic liver sec-
tion was displayed on the screen ofa Zeiss
(Oberkochen, Germany) Videoplan moni-
tor using a Hitachi CCTV camera mount-
ed on a Zeiss light microscope with a 1x
objective. Using the Videoplan digitizer
tablet, stylus, and the data acquisition pro-
gram, the Videoplan system calculated the
total area ofthe liver section after drawing
the outline of the liver. Next, the Video-
plan system calculated the percentage of
liver necrosis (% of total liver showing
necrosis) after drawing the outline of the
necrotic areas in the liver section. For each
experimental liver, we examined two liver
sections; each section was measured twice,
and a meanvaluewas calculated from these
four determinations. A tissue control and a
constructed square control were examined
before analyzing experimental samples.
Using a square with sections of20, 40, 60,
80, and 100% drawn on graph paper as a
template, the accuracy ofthe Videoplan in
determining the area of each section (ex-
pressed as a % ofthe total area) with a 2%
error was confirmed daily. Using a liver
section control (from a CC14-treated rat),
the accuracy and reproducibility of the
Videoplan and its operator were confirmed
daily. We analyzed this control liver sec-
tion for percent liver necrosis on five sepa-
rate occasions with a mean and SE of52.7
+ 2.2%. Before analyzing experimental
samples, we determined the percent necro-
sis in the liver control section within 2 SEs
ofthe calculated meanvalue (48-57%).
To determine the effect of tocopherol
analog administration on the acute toxicity
ofCCI4, we estimated the LD 0 by a mod-
ified up-and-down method o Dixon (15)
and Bruce (16). In brief, the dose ofCC14
administered was adjusted by a factor of
1.3 until successive lethal and nonlethal
doses were found. The true LD value for
each treatment is assumed to f5?l between
these successive CC14 doses with opposite
effects. The initial dosewas 2.9 gCCl4/kg,
and survival was monitored for at least 7
days after CC14 treatment to ensure recov-
ery.
Tissue concentrations of T, TA, and
TS were determined by the HPLC method
of Fariss et al. (1). Liver, brain, kidney,
heart, and lung were prepared for analysis
by a freeze-clamp technique (immediately
frozen with liquid N2, pulverized to apow-
der with a mortar and pestle, and stored at
-800C). For analysis, 25-50 mg of pow-
dered tissue was weighed (or 100 ,ul of
plasma or blood added) in a microcen-
trifuge tube and treated as described for
Volume 101, Number6, November 1993 529viable hepatocytes in the previous method
(1). We determined the tissue concentra-
tion ofT from the initial tissue extraction,
and the T ester concentration (TS or TA)
was determined by measuring the amount
of T released from base hydrolysis of the
first extract (1). A standard curve for each
tocopherol analog was analyzed with each
set ofexperimental samples. The limit of
detection for T, TA, and TS by this meth-
od is 10 nmol/g tissue and 5 nmol/ml plas-
ma or blood.
We investigated the effect of TS and
CS on microsomal drug metabolism using
the pentobarbitone (PB) sleeping-time test
(17. Male Sprague Dawley rats (160-200
g) were given an intraperitoneal injection
of vehicle (olive oil); TS in olive oil
(100mg/kg); cholesterol in olive oil (64
mg/kg) plus tris succinate in saline (59
mg/kg); or CS, tris salt in saline (100
mg/kg) plus olive oil (same dose as C treat-
ment) and fasted for 24 hr. Next, PB (50
mg/kg, intraperitoneally) was administered
to each rat, and the sleeping time was
recorded. The absence of the animal's
righting reflex was used to indicate sleep.
At the start ofsleeping time, we placed the
animal in the supine position, and the
sleeping time ended once the animal
assumed a prone position. As a control, an
inhibitor of cytochrome P-450, metyr-
apone (100 mg/kg) or its vehicle (corn oil)
was administered intraperitoneally to rats
30 min before PB (50 mg/kg), and the
sleeping time was determined. The pre-
treatment regimen of each animal was
unknown to the investigator during the
sleeping time determination.
Data were analyzed for significance
(p<0.05) using single-factor analysis of
variance (ANOVA) and Scheffe's multiple
comparison test (StatView II for Macin-
tosh, version 1.04, Abacus Concepts Inc.,
Berkeley, California). The Student's t test
(unpaired) was used to determine the sig-
nificant difference (p<0.05) between the
two treatments in each PB sleeping time
experiment.
Results
The estimated LD50 determined for CC14
was 2.5 g/kg in rats receiving vehicle pre-
treatment (Table 1). Rats pretreated with
a single dose of T or TA (100 mg/kg)
before an oral gavage of CC14 were not
afforded protection against the lethal
effects of this chlorohydrocarbon. In fact,
the administration ofunesterified T poten-
tiated CC14 acute toxicity (estimated LD50
of 1.5 g/kg). In contrast, rats pretreated
with TS (100 mg/kg) were protected
against CCI4-mediated toxicity as demon-
strated by a 76% increase in the estimated
LD50 to 4.4 g/kg (Table 1). Interestingly,
when TS was administered orally, no pro-
Table2. Effect oftocopherol analog administration on CCI4 hepatotoxicity
Serum enzyme concentration
Tocopherol analog AST ALT Liver necrosis Tissue concentration
administereda (103U/I) (103U/L) (% of liver) Liver Fat
Vehicles
(noCCI4) 0.07±0.01 0.03±0.00 0 T 48±2 42±13
T ester ND ND
Vehicle
(+ CCI4,2.9 g/kg) 15.60 ± 5.11 2.82 ± 1.65 57.7 ± 8.9 T 51 ±4 66± 14
Tester ND ND
Tocopherol
(+ CCI4 1.7g/kg) 17.33 ± 7.22 4.68 ± 0.29 62.4 ± 3.5 T 60 ± 9 397± 80**
T ester ND ND
Tocopheryl
acetate
(+ CCI4 2.9 g/kg) 20.22 ± 3.52 6.11 ± 0.42 50.9 ± 7.2 T 85 ±3 76 ± 8
TA ND ND
Tocopheryl
succinate
(+ CCI4 2.9g/kg) 3.43 ± 1.50* 0.63 ± 1.17* 28.7 ±0.9** T 117 ± 15* 124 ± 16
TS ND 47±20
8Tocopherol analogs and vehicle were administered (100 mg/kg, ip) 24 hr before a single oral dose of
CCI4. Rats were fasted 24 hr before CCI4 administration. Liver necrosis, tissue T, and T ester levels and
serum AST and ALT levels were determined in specimens obtained 48 hr after CC14treatment. Values are
the means ± SEM (n= 3-4). ND, notdetermined.
*p< 0.05, as compared to otherCCI4treatments.
**p <0.001, as compared to otherCCI4treatments.
Table 3. Tissue concentrations oftocopherol and tocopherol esters, 24 and 48 hr aftertocopherol analog
administration
Tocopherol analog Tissue concentration (nmol/g)a
administered Liver Brain Kidney Heart Lung Blood Plasma
Vehicle T 28±3 27±1 35±5 27±5 47±1 10±1 13±1
24 hr after Tester ND ND ND ND ND ND ND
Tocopherol T 128± 10* 32±2 41±2 36±3 70±6 16± 1 20±2
(100 mg/kg, ip) T ester ND ND ND ND ND ND ND
Tocopherylacetate T 56±10 34±5 35±1 43±4 54±3 22±1 18±1
(l00mg/kg,ip) TA 92±6 ND 30±8 37±2 74±4 7±2 6±2
Tocopheryl succinate T 51 ±5 34 ±3 25± 1 31 ±2 42 ±2 13 ±0 14± 2
(l00mg/kg,ip) TS 119±16 ND 31±6 47±3 90±1 7±1 8±1
Tocopherylsuccinate T 66±12 42±4 39±2 62±2 63±4 16±1 14±1
(100 mg/kg,oral) TS ND ND ND ND ND ND ND
Vehicle T 38±6 34±3 35±3 47±5 54±9 11±2 9± 1
48 hr after Tester ND ND ND ND ND ND ND
Tocopheryl succinate T 66 ±6 nd 39 ±4 38± 10 88 ±3 19 ±2 20± 1
(100 mg/kg, ip) TS 30± 53 nd ND ND ND ND ND
48 hrafter
Values arethe means ± SEM (n=3-4). ND, notdetected; nd, not determined.
*p<0.001, as compared to othertocopherol analogtreatments.
tection was observed. Histological exami-
nation of rat tissues (liver, lung, kidney,
and heart), obtained 48 hr after a lethal
dose ofCC14, demonstrated extensive peri-
portal and midzonal liver necrosis, but
histopathology was unremarkable for the
other tissues examined. Liver histology
was normal in TS-pretreated rats that sur-
vived 7 days after CC14 treatment.
The protective effect ofTS administra-
tion against CC14-induced hepatotoxicity
is shown in Table 2 and Figure 1. Each rat
received an approximate LD50 dose of
CC14 (2.9 g CCl4/kg for all treatments
except 1.7 g/kg forT-pretreated rats). Rats
pretreated with vehicle demonstrated a
massive increase in liver-associated serum
enzymes AST (15,600 U/1) and ALT
(2,820 U/1), 48 hr after CC14 administra-
tion. In addition, approximately 58% of
the liver was found to be necrotic in each
animal from this treatment group (Table
2, Fig. IB). Pretreatment ofrats with T or
TA did not significantly alter the hepato-
toxic effect ofCC14 treatment as indicated
by serum enzyme levels, percent liver
necrosis, and histopathology (Table 2, Fig.
IC). These findings are in agreement with
the acute toxicity data in that comparable
lethal doses of CC14 given to TA- and T-
pretreated rats resulted in similar hepato-
toxic damage. In contrast, rats pretreated
with TS were significantly protected from
CC14 hepatotoxicity, with serum AST and
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Figure 1. Lightmicrographs ofparaffin-embedded rat liver. Alltissues were stained with hematoxylin and eosin. (A) Representative section from rattreated with
vehicle, no pathologic changes present. (B) Representative sectionfrom rattreated with CCI4(2.9g/kg); necrosis(N) of all hepatocytes exceptthose within afew
cell layers of the portal tracts (necrosis score 3). There is ballooning degeneration at the interface (arrowheads). (C) Representative sections from rattreated
with CCI4 (1.7 g/kg) and T; identical pathologic changes asthat observed in panel B (necrosis score 3). (D) Representative section from rattreated with CCI4(2.9
g/kg) andTS; necrosis of perivenular and part of midzonal hepatocytes (necrosis score 2). The periportal and proximal midzonal hepatocytes are preserved with
little degeneration. All photographs are 50x.
ALT levels of 3430 and 630 U/1, respec-
tively (77% reduction as compared to
CC14 only treatment). Administration of
the cytoprotective agent TS also signifi-
cantly reduced CCl4-mediated hepatic
necrosis by 50% from 58% to 29% (Table
2) and appeared to limit the extent ofdam-
age (ballooning degeneration) to periportal
and proximal midzonal hepatocytes (Fig.
1D). Hepatic T levels in TS-treated rats
and fat T levels in T-treated rats were sig-
nificantly elevated as compared to the
other treatment groups 48 hr after CC14
treatment. Tocopherol esters were not
detected in the liver 48 hr after CC14 treat-
ment.
The tissue (liver, brain, kidney, heart,
lung, whole blood, and plasma) concentra-
tion of T and tocopherol esters (TA and
TS) were measured 24 hr after tocopherol
an'alog administration (no CC14), and the
results are shown in Table 3. This time
course (24 hr after) was used to determine
the tissue (liver) concentration of T, TA,
and TS at the time ofCC14 exposure. Rats
pretreated with T for 24 hrdemonstrated a
fivefold increase in the amount ofunesteri-
fied T in the liver (128 nmol/g) as com-
pared to vehide-treated rats (28 nmol/kg).
However, this T pretreatment did not
result in protection. A twofold increase in
liver T concentration was observed with
TA and TS pretreatments, but only the
administration ofTS resulted in protection
against CC14 toxicity and hepatic TS accu-
mulation (Table 3). Thus, TS-mediated
Volume 101, Number 6, November 1993 531protection appears to depend on the hepa-
tocellular accumulation ofTS. This con-
clusion was confirmed by our finding that
the oral administration of TS eliminates
both protection and liver and tissue accu-
mulation ofTS (Table 3). Furthermore,
the tissue distribution results in Table 3
demonstrate that 24 hr after a single dose
of TS (100 mg/kg), a significant (p<0.05
versus vehicle control) accumulation ofTS
was found in all tissues examined, except
the brain. However, 48 hr after TS ad-
ministration, tissue TS levels were not
detectable or were not significantly differ-
ent from vehicle control.
To investigate the importance of the
tocopherol molecule in cytoprotection, we
also examined the protective properties of
another lipophilic hemisuccinate deriva-
tive, CS, as well as unesterified cholesterol
and CA. Data from these studies (Table 4)
clearly demonstrate that CS tris salt is a
powerful protective agent against the hepa-
totoxic effects of a sublethal dose of CC14
(1 g/kg). In fact, CS pretreatment com-
pletely protected rats from hepatotoxicity
at 24, 48, and 72 hr after CC14 exposure as
measured by serum ALT levels and hepat-
ic necrosis. However, cholesterol or CA
pretreatment did not significantly protect
rats from the hepatotoxic effects of CC14
administration (Table 4). A histological
examination of the hepatic terminal ven-
ules (Fig. 2) revealed that treatment with 1
g CCI4/kg results in perivenular necrosis
and collapse (necrosis score 1) with large
globule fatty degeneration of midzonal
hepatocytes (fat globules turn black with
osmium postfixation; Fig. 2B). In contrast,
CS pretreatment prevented CCl4-induced
Table4. Effectofcholesterol analog administration on CCI4-induced hepatotoxicity
Serum ALT (103 U/L) Hepatic necrosis
Cholesterol analog administered" 24 hr 48 hr 72 hr score (0-4)
Vehicles
(no CC14) 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0 ± 0
Vehicle
(+ CCI4) 0.55 ± 0.14 0.92 ± 0.14 0.10 ± 0.01 1 ± 0
Cholesterol
(+CCI4) 1.45±0.34 1.16±0.41 0.11 ±0.04 1 ±0
Cholesteryl acetate
(+CCI4) 0.83±0.38 0.96±0.32 0.11 ±0.04 1 ±0
Cholesteryl succinate
tris salt(+ CC14) 0.04 ± 0.01* 0.02 ± 0.0* 0.02 ± 0.0* 0 ± 0
aCholesterol analogs and vehicle were administered (100 mg/kg, ip) 24 hr before a single oral dose ofCCI4
(1.0 g/kg). Rats were fasted 24 hr before CCI4 administration. Serum ALT levels were determined at 24,
48, and 72 hr after CCI4 treatment. The liver necrosis score was determined from specimens obtained 72
hr after CCI4treatment. Values arethe means ± SEM (n=3-5).
*p<0.01, as compared to otherCCI4treatments.
perivenular necrosis (necrosis score 0) and
dramatically reduced the fattydegeneration
ofhepatocytes (Fig. 2C).
To determine the influence of fasting
on the cytoprotective capacity of TS and
CS, rats were pretreated with TS, CS, tris
salt, or cholesterol plus sodium succinate
plus trizma base and fed for 24 hr before
CC14 administration (2 g/kg). Data from
these studies (Table 5) demonstrate that CS
tris salt pretreatment completely protected
fed rats from hepatotoxicity at 24, 48, and
72 hr after CC14 exposure as measured by
serum ALT levels and hepatic necrosis.
However, TS and cholesterol plus succinate
plus trizma pretreatments did not afford
rats significant hepatoprotection. Inter-
estingly, fed rats given 2 g CCl4/kg demon-
strated less hepatic damage with greater
variability (ALT levels) within treatment
groups than fasted rats receiving 1 g
CCl4/kg (Table 4). In both fed and fasted
rats, liver damage (as measured byALT lev-
els) was observed predominantly at 24 and
48 hr after CC14 exposure, but peak en-
zyme leakage varied within a treatment
group between these two time points.
Though serum ALT levels returned to near
control levels by 72 hr after CC14 treat-
ment, hepatic necrosis was still detectable
by histopathology at this time point
(Tables 4 and 5).
Because of the striking protective
capacity ofCS tris salt, the protective abili-
ties ofthe free acid and tris salt ofTS were
compared with CS tris salt and TN pre-
treatment against a sublethal hepatotoxic
dose of CC14 (1 g/kg). The results of this
study, shown in Table 6, indicate that the
administration ofTN and TS free acid did
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Figure 2 Light micrographs of plastic-embedded rat liver, postfixed in osmium tetroxide and stained with toluidine blue. (A) Vehicle control (saline, no CCI4):
hepatic terminal venule showing normal hepatocytes with infrequent and small fat globules (black). (B) CCI4-treated group (1 g/kg): hepatic terminal venule with
perivenular necrosis (N) and collapse with large globule fatty degeneration (arrowhead) of midzonal hepatocytes, (necrosis score 1). (C) CCI4- (1 g/kg) and CS-
treated group: hepatic terminal venule with ballooning and fatty degeneration of perivenular hepatocytes with occasional hepatocellular necrosis or dropout.
Midzonal cells, atperiphery, are intactwith infrequentfatglobules (necrosis score 0). All photographs are 280x.
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Table 5. Effect oftocopherol and cholesterol analogs on CCI4-induced hepatotoxicity in fed rats
Serum ALT (103 U/I) Hepatic necrosis
Cholesterol analog administered" 24 hr 48 hr 72 hr score (0-4)
Vehicles
(no CCI4) 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0 ± 0
Vehicle
( + CC14) 0.26 ± 0.13 0.39 ± 0.28 0.08 ± 0.04 0.5 ± 0.5
Tocopheryl succinate
( + CCI4) 0.32 ± 0.34 0.53 ± 0.38 0.07 ± 0.04 0.75 ± 0.5
Cholesterol +tris
+ succinate ( + CCI4) 0.31 ± 0.17 0.48 ± 0.24 0.10± 0.04 0.75 ±0.5
Cholesteryl succinate,
tris salt(+CCI4) 0.05 ± 0.02* 0.03 ± 0.01* 0.03 ± 0.0* 0 ± 0
'Tocopherol and cholesterol analogs and vehicle were administered (100 mg/kg, ip) 24 hr before a single
oral dose of CC14(2.0 g/kg). Rats were fed before CCI4 administration. Serum ALT levelswere determined
at24, 48, and 72 hr after CCI4treatment. The liver necrosis score was determined for specimens obtained
72 hr after CCI4treatment. Values arethe means ± SEM (n=4-5).
*p<0.01 as compared to vehicle (+CCI4).
Table 6. Effectoftocopherol and cholesterol analogs on CCI4-induced hepatotoxicity
Serum enzyme concentration
AST ALT Hepatic necrosis
Analog administereda (103 U/I) (103 U/I) score (0-4)
Vehicles
(no CC14) 0.11 ±0.03 0.05 ± 0.01 0± 0
Vehicle (olive oil)
(+ CCI4) 4.41 ± 2.05 1.95 ± 0.71 2.0 ± 1.0
Tocopheryl nicotinate
(+ CCI4) 4.95 ± 1.38 2.12 ± 0.52 ND
Tocopheryl succinate,
free acid (+ CCI4) 2.06 ± 0.53 1.08 ± 0.23 1.25 ± 0.50
Tocopheryl succinate,
tris salt(+ CCI4) 0.79 ± 0.26* 0.52 ± 0.16* 1.0 ± 0.0
Cholesteryl succinate,
tris salt(+ CCI4) 0.14 ± 0.02** 0.06 ± 0.01** 0.25 ± 0.50
8Tocopherol and cholesterol analogs and vehicle were administered (100 mg/kg, ip) 24 hr before a single
oral dose of CCI4(1.0 g/kg). Rats were fasted 24 hr before CCI4 administration. Serum AST and ALT levels
and liver necrosis were determined in specimens obtained 48 hr after CCI4treatment. Values are the
means ± SEM (n = 3-5). ND, notdetermined.
*p< 0.01 as compared to vehicle (+CCI4).
**p<0.001 as compared to vehicle (+CCI4).
Table 7. Effect oftocopheryl succinate and cholesteryl succinate administration on pentobarbitone (PB)
sleeping time in the rat
Sleeping time
Experiment Pretreatmenta (min)
1 Vehicle (corn oil) 120 ±9
Metyrapone (100 mg/kg, ip) 900 ± 120
2 Vehicle (olive oil) 72 ± 14
TQcopheryl succinate, free acid (100 mg/kg, ip) 86 ± 1
3 Cholesterol (64 mg/kg, ip) and tris succinate (59 mg/kg, ip) 117 ± 30
Chofesteryl succinate, tris salt(100mg/kg, ip) 148 ± 40
8The pretreatment compQunds were administered and ratsfasted for24 hr before a single dose of PB (50
mg/kg, ip). Metyrapone orvehicle (corn oil) were given 30 min before PB. Values arethe means ± SEM
(n=3-5).
not afford rats significant protection
against the hepatotoxic effects of CC14.
The percent protection [as determined by
ALT values with negative (no CC14) and
positive (+CCl4) controls assumed to be
100% and 0% protection] for TN and TS
free acid were 0% and 46%, respectively.
In contrast, the administration of the tris
salt form ofTS provided highly significant
hepatoprotection (75% protection). How-
ever, the tris salt of CS proved to be the
most effective protective agent tested, pro-
viding virtually complete protection
against CCl4-mediated hepatotoxicity.
To assess the effect ofTS and CS pre-
treatment on hepatic drug metabolism, the
influence ofthese cytoprotective agents on
pentobarbitone-mediated sleeping time in
the rat was determined (Table 7). The pre-
treatment of rats with metyrapone, a
known inhibitor of cytochrome P-450-
mediated drug metabolism, resulted in a
650% increase in PB sleeping time. How-
ever, a significant increase in PB sleeping
time was not observed in rats pretreated
with TS free acid (19% increase) or CS tris
salt (26% increase) as compared to vehicle
controls and nonprotective conditions
(cholesterol and tris succinate).
Discussion
Because exposure to CC14 results in exten-
sive cellular lipid peroxidation, numerous
investigators have examined the protective
role ofcellular a-tocopherol, the predomi-
nant membrane-bound antioxidant and
free radical scavenger, in CCl4-induced
hepatotoxicity. Attempts to supplement
endogenous stores of cellular T, however,
have resulted in conflicting reports on the
cytoprotective abilities of vitamin E ad-
ministration against CC14 toxicity. The
published reports range from protection
(18-20) and no effect (20-22) to potentia-
tion (20,23) ofCC14 toxicity after vitamin
E administration. The present study dem-
onstrates distinct differences in the cyto-
protective nature of various tocopherol
analogs. As measured by survival, liver-
associated serum enzyme levels, and histo-
pathology, protection against CC14 hepato-
toxicity was not observed after pretreating
rats (24 hr) with a single dose (100 mg/kg)
ofunesterified T or the acetate and nicoti-
nate esters of T. Thus, the supplementa-
tion of hepatic T levels (fivefold increase)
in a presumably physiologically active con-
figuration (in vivo administration and dis-
position) failed to protect rats from the
toxic effects of CC14. In fact, we found
that T administration enhanced the toxic
effect ofCC14, while TA and TN adminis-
tration did not alter CCl4-mediated toxici-
ty. The variable findings, reported here
and in numerous other reports, on the pro-
tective abilities ofvitamin E administration
(18-23), illustrate the need for additional
studies on the influence ofvitamin E dos-
ing regimens on T subcellular disposition
and chemical-induced toxicity. These
studies are necessary to understand and
have confidence in the use of T or other
tocopherol analogs as a therapeutic strategy
for CC14 or other chemical poisonings.
In contrast to T, TA, and TN, the
administration of the hemisuccinate ester
of T protected rats from the lethal and
hepatotoxic effects of 2.9 g CCl4/kg body
weight and resulted in a significant accu-
mulation ofhepatocellular TS. These data
support the results and conclusions from
our previous in vitro studies, demonstrat-
ing that TS is a unique and effective cyto-
protective agent. Our finding that TS
administered orally results in no hepatic
accumulation of TS (presumably due to
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levels are elevated in the absence of tissue
TS; Table 3) and no protection against
CC14 toxicity also supports our hypothesis
that the presence ofcellular TS is essential
for cytoprotection against CC14 toxicity.
Interestingly, the protection observed for
TS free acid in rats treated with a lethal
dose of CC14 (2.9 g/kg) was not observed
when the concentration of CC14 adminis-
tered was reduced to a sublethal dose in
fasted and fed rats. Though TS free acid
pretreatment did reduce CCl4-induced
hepatotoxicity by 46% (in fasted rats)
when sublethal concentrations of CC14
were administered (Table 6), the degree of
protection was not significant (p<0.05) as
determined by ANOVA using Scheffe's
multiple comparison test. Wolfgang et al.
(21) have also reported the modest protec-
tive abilities ofTS free acid administration
against a sublethal dose of CC14. How-
ever, the administration of the tris salt of
TS did result in significant hepatoprotec-
tion (p<0.01). An explanation for the
apparent difference in the cytoprotective
abilities ofthe free acid and the tris salt of
TS is unknown. We speculate that differ-
ences in hydrophilicity between these two
forms of TS might influence the bioavail-
ability of TS after administration and
hence explain the variability in cytoprotec-
tive ability. This hypothesis is in agree-
ment with Carini and co-workers' (8)
explanation for enhanced protection
against CCl4-induced lipid peroxidation
with the water-soluble form of TS, TS
polyethylene glycol ester, as compared to
TS free acid.
One possible explanation for the
unique cytoprotective abilities ofTS is that
the subcellular distribution ofTS (as com-
pared to T administration) is distinctive,
and thus T released from TS at this novel
subcellular site is essential for protection.
In support of this hypothesis, we found
that TS pretreatment resulted in hepatic T
levels 48 hr after CC14 treatment that were
significantly higher than levels observed for
nonprotective vitamin E pretreatments
(even though these pretreatments increased
adipose T levels by 10-fold; Table 2).
These findings indicate a unique ability of
TS to maintain hepatocellular T levels dur-
ing a toxic insult or they may merely be
the result, rather than the cause, of cyto-
protection (cellular T is lost after cell
death). We support the later explanation,
but this question can only be answered in
vitro, by separating viable from nonviable
hepatocytes before analysis during a toxic
CC14 insult. To argue against a novel cel-
lular disposition for TS, our tissue distrib-
ution data, measured 24 hr after a single
dose ofT ester, does not show a significant
difference in the disposition ofTS and TA.
As shown in Table 3, similar concentra-
tions ofTS and TAwere found in each tis-
sue examined. Furthermore, the release of
T as an explanation for TS cytoprotection
does not appear to be the critical event
because the substitution of the tocopherol
portion of the TS molecule with choles-
terol results in a compound (CS) with
remarkable protective properties against
CCl4-induced hepatotoxicity. Thus, our
studies clearly demonstrate that the release
of tocopherol is not essential for the cyto-
protection observed. Because protection
was not observed after cholesterol and CA
administration, and cholesterol has no
reported antioxidant and free radical scav-
enging abilities, we again conclude that the
protection observed results from the cellu-
lar accumulation and the unique properties
of CS and TS. The protection against
CC14 hepatotoxicity observed with CS
administration was striking, with complete
protection against CC14-induced necrosis
and a dramatic reduction in fatty degenera-
tion as demonstrated by light microscopy.
These results indicate that CS pretreat-
ment not only maintained cell viability
during a toxic insult with CC14 but also
maintained hepatic function (processing of
lipid) during this insult. Like TS, the tris
salt ofCS is a more effective cytoprotective
agent than the free acid form (personal
observation). Again, we speculate that the
insoluble nature ofCS free acid appears to
preclude its protective abilities.
As we are the first to describe CS and
TS cytoprotection in vivo, little is known
about the mechanism of TS and CS pro-
tection against CCl4-mediated hepatotoxi-
city. One possible explanation is that TS
and CS pretreatments simply delay the
onset ofthe toxic response rather than pro-
vide true protection. This possibility is
unlikely because we have shown that TS
protection against the lethal effects ofCC14
continues for at least 7 days with no liver
histopathology observed at that time. In
addition, using both histopathology and
serum ALT levels, we demonstrated that
CS completely protected fed and fasted
rats from the hepatotoxic effects of CC14
for 72 hr (a period oftime in which serum
AST levels, for CCl4-treated rats without
protection, have nearly returned to normal
endogenous levels). It is important to point
out the advantages of using both liver
histopathology and serum ALT levels to
assess hepatotoxicity. We have found, in
agreement with previous reports, that the
time course of hepatic AST leakage after
CC14 treatment can vary significantly from
animal to animal in a treatment group.
Whereas the leakage ofcellular enzymes is
a transient event, liver necrosis is evident
for 3-5 days. Thus, by determining the
extent ofliver necrosis (score) 48 or 72 hr
after a CC14 insult, in combination with
serum enzyme levels, we gain considerable
confidence in reporting the degree ofhepa-
totoxicity or hepatoprotection.
Because the hepatic metabolism of
CC14 is essential for the expression ofCC14
toxicity, one obvious explanation for this
protection would be the inhibition ofdrug
metabolism by CS and TS administration.
Previous reports have demonstrated that
numerous drugs that potentiate or inhibit
CC14 toxicity similarly affect the metabo-
lism of pentobarbitone, resulting in a
decrease or increase in sleeping time,
respectively (24-27). As our studies
demonstrated no significant alteration in
pentobarbitone sleeping time after CS or
TS pretreatment, we conclude that inhibi-
tion of CC14 metabolism probably is not
responsible for the cytoprotection observed
with these compounds. However, addi-
tional studies examining the effect ofthese
protective agents on hepatic P-450 IIEI
activity and spectral P-450 levels are
required.
Another possible explanation for the
unique protective properties observed after
TS and CS pretreatment is the release of
succinate from hepatocellular TS or CS.
Previous studies indicate that the adminis-
tration of succinate can protect mitochon-
dria, cells, and organisms from a variety of
toxic insults (28-30) and that succinate is
a preferred mitochondrial substrate with
respect to energy production (oxidative
phosphorylation) and the reduction of
pyridine nucleotides (31,32). Because the
cellular uptake and accumulation ofsucci-
nate is severely limited by its hydrophilicity
(33), the administration oflarge concentra-
tions of succinate (g/kg body weight, in
vivo) are required to alter the cellular ener-
gy status or provide cytoprotection. In
contrast, the administration of TS or CS
provides a lipophilic carrier for succinate,
thus promoting both cellular uptake and
accumulation. Interestingly, Simon et al.
(34) reported that the majority of intra-
venously administered TS was found as
intact TS in the hepatic microsomal and
mitochondrial fractions. In the present
study, we found that approximately 120
nmol succinate/g liver is released from
hepatocellular TS during a 24-hr period
(the hepatic TS concentration at 24 and 48
hr after TS administration were 120
nmol/g and 0 nmol/g ,respectively; Table
3). Assuming that the normal endogenous
succinate concentration in fasted rat liver is
170 to 270 nmol/g (35,36), the amount of
succinate released from hepatocellular TS
would result in a 45-70% increase in suc-
cinate levels over a 24-hr period. This sub-
stantial increase in succinate, released and
used in the hepatocyte, might enable the
maintenance of cellular metabolic and
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repair processes required for survival dur-
ing a toxic CC14 insult. Additional experi-
mental evidence will be required to con-
firm the role of succinate in TS and CS
protection against CCl4-induced hepato-
toxicity. Because an analytical method to
measure tissue CS concentrations has not
yet been developed, we can only assume
(due to common physicochemical proper-
ties) that the hepatic accumulation and dis-
positon of CS is similar to that found for
TS.
A final explanation for TS- and CS-
mediated hepatoprotection is that the
amphipathic TS and CS molecules are the
protective agents. Data from the present
study suggest that the ionic nature ofTS or
CS is important for protection. If the
acidic nature of the tocopherol or choles-
terol molecule is eliminated, as seen with
T, TA, TN, C or CA, the protective prop-
erties of these compounds are eliminated.
Similar findings were also reported in our
previous in vitro studies on TS-mediated
cytoprotection (1,5,6). Once in the cell,
the TS and CS molecules might alter
membrane stability or function by interact-
ing with membrane-bound proteins and/or
with the unsaturated fatty acid portion of
phospholipid (tocopherol or cholesterol
portion) as well as with the polar region of
the phospholipid (ionic succinate moi-
ety)(37). In fact, a unique membrane-
associated property of TS and CS (not
found with other nonionic cholesterol or
tocopherol analogs) is their ability to spon-
taneously form multilamellar liposomes
(bilayers) in aqueous solution (13). How-
ever, this bilayer organization ofTS can be
disrupted by increasing the calcium con-
centration to 2.5 mM or greater (38).
This calcium concentration (>2.5mM) also
eliminated TS-induced protection against
toxic injury in isolated hepatocytes (1).
Numerous reports indicate that TS and
CS administration do indeed stabilize
membranes (13,37,39-41) and alter mem-
brane enzymatic and receptor activity
(40-45). For example, Brase and Westfall
(42) reported that the addition ofTS stim-
ulates rat liver phenylalanine hydroxylase
activity, while Chelliah and Fariss (44)
have recently discovered that both TS and
CS are potent inhibitors ofpurified electric
eel-derived acetylcholinesterase activity but
not butyrylcholinesterase activity. Num-
erous reports also attest to the effect ofCS
on the physical state ofcellular membranes
(increased viscosity), which can influence a
variety of membrane functions (39-41).
For example, Levy et al. (39) demonstrated
a marked reduction in cellular ion leakage
after human erythrocyte membranes were
enriched with CS. Kolena and Kasal (40)
reported that the incubation of rat testicu-
lar membranes with CS and other dicar-
boxylic acid esters ofcholesterol resulted in
an increase in both membrane lipid micro-
viscosity and in human chorionic gonado-
tropin (hCG)-receptor binding. The elim-
ination ofthe free carboxylic acid group of
CS and the other cholesterol esters abol-
ished their stimulatory effect on both the
leutenizing hormone/hCG receptor and
membrane microviscosity. Using synapto-
somal brain membranes, Lazar and
Medzihradsky (41) demonstrated that the
addition of CS restored the microviscosity
and opioid receptor binding capacity of
membranes fluidized by fatty acids. It is
well known that numerous physiological
and pathological conditions, including
CC14 toxicity (46-48), can modulate the
lipid composition and fluidity ofbiological
membranes resulting in diminished struc-
tural integrity and altered membrane-
bound enzyme activity (e.g., calcium
ATPase activity). We speculate that the
activity of CS and TS on cellular mem-
branes, as described above, might prevent
or reverse the membrane solvent effect (49)
and lipid peroxidative (46-48) effect asso-
ciated with CC14 hepatotoxicity.
In summary, we have found that sup-
plementation ofendogenous unesterified T
levels does not protect the liver from the
toxic effects of CC14 In contrast, the
administration of the succinate esters of
tocopherol and cholesterol afford rats pro-
tection against CCl4-induced toxicity. In
fact, rats pretreated with CS were com-
pletely protected from CCl4-mediated liver
damage. The observed protection appears
to depend on the hepatocellular accumula-
tion ofTS and CS and does not appear to
be related to an alteration in hepatic drug
metabolism. Future investigations on the
mechanism of CS and TS protection
against CC14 toxicity should provide valu-
able information about the critical cellular
events responsible for CC14 toxicity and
potential strategies to protect ourselves
from this toxic chemical and other chloro-
hydrocarbons.
REFERENCES
1. Fariss MW, Merson MH, O'Hara TM. Alpha
tocopheryl succinate protects hepatocytes from
chemical-induced toxicity under physiological
calcium conditions. Toxicol Lett 47:61-76
(1989).
2. Fariss MW, Pascoe GA, Reed DJ. Vitamin E
reversal ofthe effect ofextracellular calcium on
chemically induced toxicity in hepatocytes.
Science 227:751-754(1985).
3. Pascoe GA, Olafsdottir K, Reed DJ. Vitamin E
protection against chemical-induced cell injury
I. Maintenance of cellular protein thiols as a
cytoprotective mechanism. Arch Biochem
Biophys 256:150-158(1987).
A Pascoe GA, Reed DJ. Vitamin E protection
against chemical-induced cell injury II. Ev-
idence for a threshold effect of cellular alpha-
tocopherol in prevention ofAdriamycin toxici-
ty. Arch Biochem Biophys 256:159-166(
1987).
5. Fariss MW. Oxygen toxicity: unique cytopro-
tective properties of vitamin E succinate in
hepatocytes. Free Rad Biol Med 9:333-343
(1990).
6. Fariss MW. Cadmium toxicity: unique cyto-
protective properties ofalpha tocopheryl succi-
nate in hepatocytes. Toxicology 69:63-77
(1991).
7. Dogterom P, Nagelkerke JF, Mulder GJ.
Hepatotoxicity of tetrahydroaminoacridine in
isolated rat hepatocytes: effect of glutathione
and vitamin E. Biochem Pharmacol 37:2311-
2313(1988).
8. Carini R, Poli G, Dianzani MU, Maddix SP,
Slater TF, Cheeseman KH. Comparative evalu-
ation ofthe antioxidant activity of alpha-toco-
pherol, alpha-tocopherol polyethylene glycol
1000 succinate and alpha tocopherol succinate
in isolated hepatocytes and liver microsomal
suspensions. Biochem Pharmacol 39:1597-
1601(1990).
9. Gogu SR, Beckman BS, Rangan SRS, Agrawal
KC Increased therapeutic efficacy of Zidov-
udine in combination with vitamin E Biochem
Biophys Res Commun 165:401-407(1989).
10. Gogu SR, Lertora JJL, George WJ, Hyslop
NE, Agrawal KC. Protection of Zidovudine-
induced toxicity against murine erythroid prog-
enitor cells by vitamin E. Exp Hematol 19:
649-652(1991).
11. Sugiyama M, Ando A, Ogura R. Effect ofvita-
min E on survival, glutathione reductase and
formation of chromium (V) in Chinese ham-
ster V-79 cells treated with sodium chromate
(VI). Carcinogenesis 10:737-741(1989).
12. Sugiyama M, Tsuzuki K, Matsumoto K,
Ogura R. Effect of vitamin E on cytotoxicity,
DNA single strand breaks, chromosomal aber-
rations, and mutation in Chinese hamster V-79
cells exposed to ultraviolet B light. Photochem
Photobiol 56:31-34(1992).
13. Janoff AS, Kurtz CL, Jablonski RL, Minchey
SR, Boni LT, Gruner SM, Cullis PR, Mayer
LD, Hope MJ. Characterization of cholesterol
hemisuccinate and alpha tocopherol hemisucci-
nate vesicles. Biochim Biophys Acta 941:165-
175(1988).
14. Bergmeyer HU, Scheibe P, Wahlefeld AW.
Optimization of methods for aspartate amino-
transferase and alanine amino-transferase. Clin
Chem 24:58-73(1978).
15. Dixon WJ. The up-and-down method for
small samples. J Am Stat Assoc 40:967-978
(1965).
16. Bruce RD. An up-and-down procedure for
acute toxicity testing. Fundam AppI Toxicol
5:151-157(1985).
17. Guarner F, Boughton-Smith NK, Blackwell
GJ, Moncada S. Reduction by prostacyclin of
acetaminophen-induced liver toxicity in the
mouse. Hepatology 8:248-253(1988).
18. Gallagher CH. Protection by antioxidants
against lethal doses of carbon tetrachloride.
Nature 192:881-882(1961).
19. Biasi F Albano E, Chiarpotto E, Corongiu FP,
Pronzato MA, Marinari UM, Parola M,
Dianzani MU, Poli G. In vivo and in vitro evi-
dence concerning the role oflipid peroxidation
in the mechanism of hepatocyte death due to
carbon tetrachloride. Cell Biochem Funct
9:111-118(1991).
20. Cawthorne MA, Bunyan), Sennitt MV, Green
J, Grasso P. Vitamin E and hepatotoxic agents
3. Vitamin E, synthetic antioxidants and car-
bon tetrachloride toxicity in the rat. Br J Nutrr
24:357-384(1970).
Volume 101, Number 6, November 1993 535m
21. Wolfgang GHI, Jolly RA, Donarske R, Petry
TW. Inhibition of carbon tetrachloride-
induced lipid peroxidation by novel antioxi-
dants in rat hepatic microsomes: Dissociation
from hepatoprotective effects in vivo. J
Biochem Toxicol 5:167-174(1990).
22. Yasuda H, Izumi N, Shimada 0, Kobayakawa
T, Nakanishi M. The protective effect oftimo-
ridine against carbon tetrachloride hepatotoxic-
ity. Toxicol Appl Pharmacol 52:407-413
(1980).
23. Ning T. Appraisal of the protective effect of
vitamin E against CC14 liver poisoning.
ChineseJ Prev Med 23:7-8(1989).
24. Leibman KC. Effects of metyrapone on liver
microsomal drug oxidations. Mol Pharmacol
5:1-9(1969).
25. Ugazio G, Koch RR, Recknagel RO. Mech-
anism of protection against carbon tetrachlo-
ride by prior carbon tetrachloride administra-
tion. Exp Mol Pathol 16:281-285(1972).
26. Garner RC, McLean AEM. Increased suscepti-
bility to carbon tetrachloride poisoning in the
rat after pretreatment with oral phenobarbi-
tone. Biochem Pharmacol 18:645-650(1969).
27. Cignoli EV, Castro JA. Effect of inhibitors of
drug metabolizing enzymes on carbon tetra-
chloride hepatotoxicity. Toxicol AppI Pharm-
acol 18:625-637(1971).
28. Sanders AP, Hall JH, Woodhall B. Succinate:
protective agent against hyperbaric oxygen tox-
icity. Science 150:1830-1831 (1965).
29. Maliuk VI, Molotkow VN, Korzhov VI.
Metabolic disorders in acute poisoning and
their correction by sodium succinate. Vrach
Delo 8:66-68(1981).
30. Tretter L, Szabados G, Ando A, Horvath I.
Effect ofsuccinate on mitochondrial lipid per-
oxidation. 2. The protective effect ofsuccinate
against functional and structural changes
induced by lipid peroxidation. J Bioenerg
Biomembr 19:31-44(1987).
31. Chance B, Hollunger G. The interaction of
energy and electron transfer reactions in mito-
chondria. 1. General properties and nature of
the products of succinate-linked reduction of
pyridine nucleotides. J Biol Chem 236:1534-
1543(1961).
32. Kondrashova MN, Gogvadze VG, Medvedev
BI, Babsky AM. Succinic acid oxidation as the
only energy support of intensive calcium
uptake by mitochondria. Biochem Biophys Res
Commun 109:376-381(1982).
33. Mapes JP, Harris RA. On the oxidation ofsuc-
cinate by parenchymal cells isolated from rat
liver. FEBS Lett 51:80-83(1975).
34. Simon EJ, Gross CS, Milhorat AT. Intra-
cellular distribution of radioactivity following
intravenous administration of 14C_labeled vita-
min E. Fed Proc 16:249(1957).
35. Williamson JR, Corkey BE. Assays ofinterme-
diates of the citric acid cycle and related com-
pounds by fluorometric enzyme methods. In:
Methods in enzymology, vol 13 (Lowenstein
JM, ed). New York:Academic Press, 1969;
434-513.
36. Siess EA, Wieland OH. Subcellular distribu-
tion of guanine and uracil nucleotides and of
succinate in normal and glucagon-stimulated
hepatocytes. Hoppe-Seyler Z Physiol Chem
360:1677-1681(1979).
37. Lai MZ, Duzgunes N, Szoka FC. Effects of
replacement of the hydroxyl group of choles-
terol and tocopherol on the thermotropic
behavior of phospholipid membranes. Bio-
chemistry 24:1646-1653(1985).
38. Boni LT, Perkins WR, Minchey SR, Bolcsak
LE, Gruner SM, Cullis PR, Hope MJ, Janoff
AS. Polymorphic phase behavior ofalpha-toco-
pherol hemisuccinate. Chem Phys Lipids
54:193-203(1990).
39. Levy R, Hevroni D, Cabantchik ZI, Livne A.
Li-Na countertransport and Li leak in erythro-
cytes are differentially affected by membrane
enrichment with cholesteryl hemisuccinate.
Biochim Biophys Acta 854:325-328(1986).
40. Kolena J, Kasal A. Effects of cholesteryl esters
on the accessibility of LH/hCG receptors
membrane lipid fluidity in rat testes. Biochim
Biophys Acta 979:279-286(1989).
41. Lazar DF, Medzihradsky F. Altered microvis-
cosity at brain membrane surface induces dis-
tinct and reversible inhibition ofopioid recep-
tor binding. J Neurochem 59:1233-1240
(1992).
42. Brase DA, Westfall TC. Stimulation ofrat liver
phenylalanine hydroxylase activity by deriva-
tives of vitamin E. Biochem Biophys Res
Commun 48:1185-1191(1972).
43. Nwankwoala RNP, West WL. Inhibition of
alpha tocopherol and calcium calmodulin-
stimulated phosphodiesterase activity in vitro
by anthracyclines. Clin Exp Pharmacol Phys
15:805-814(1988).
44. Chelliah J, Fariss MW. Anti-cholinesterase
activity oftetrahydroaminoacridine, tocopheryl
hemisuccinate and cholesteryl hemisuccinate.
Toxicologist 13:176(1993).
45. Torelli S, Masoudi F, Prasad KN. Effect of
alpha tocopheryl succinate on cyclic AMP-
dependent protein kinase activity in murine B-
16 melanoma cells in culture. Cancer Lett
39:129-136(1988).
46. Recknagel RO, Glende EA Jr, Waller RL,
Lowrey K. Lipid peroxidation: Biochemistry,
measurement, and significance in liver cell
injury. In: Toxicology of the liver (Plaa G,
Hewitt WR, eds). Raven Press:New York,
1982;213-241.
47. Mourelle M, Meza MA. CC14-induced lipo-
peroxidation triggers a lethal defect in the liver
plasma membranes. J Appl Toxicol 10:23-27
(1990).
48. Thomas PD, Poznansky MJ. Lipid peroxida-
tion inactivates rat liver microsomal glycerol-3-
phosphate acyl transferase. J Biol Chem
265:2684-2691(1990).
49. Berger ML, Bhatt H, Combes B, Estabrook
RW CC14-induced toxicity in isolated hepato-
cytes: the importance of direct solvent injury.
Hepatology6:36-45(1986).
IvanNealhasputout
alot offires.
He's nota
firefighter-
he'sateacher. Butto the
kids he'sreached, he'sahero.
BE A SACHER. BE A HERO.
APLf t Call 1-800-45-TEACH. wjorftftm
Po RbSh i
Photo: 'RobinSachs _ @ _=XWM
536 Environmental Health Perspectives